Date:9/29/2010

in progress (5,749,230) (4,179,902) Additions to intangible assets-drug (2,742,729) (2,417,250) Advance payments for intangible assets-drug -- (1,188,115) Net cash used in investing activities (8,845,245) (7,843,281) Cash flows from financing activities: Proceeds from short-term bank loans 66,002 -- Additional paid-in capital 8,894,828 -- Dividend declared and paid (1,409,079) (73,944) Treasury stock -- (111,587) Proceeds from minority shareholders 440,010 -- Net cash provided by (used in) financing activities 7,991,761 (185,531) Effect of foreign currency translation on cash 110,229 (13,113) Net increase in cash and cash equivalents 14,656,843 295,073 Cash and cash equivalents at beginning of year 12,352,223 12,057,150 Cash and cash equivalents at end of year $27,009,066 $12,352,223 Supplemental schedule of non-cash activities Advance payments for intangible assets-drug $808,152 $--
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Tianyin Corporate Presentation Updated
2. Tianyin Reports Record Third Quarter 2010 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
4. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
5. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
9. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets